Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 7/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074418 | 0.97 | PGR (0.43) | PGRKDM1ANR3C1ARTRPA1 | |
| SCHEMBL25623168 | 0.87 | KDM1A (0.40) | PGRKDM1ANR3C1ARTRPA1 | |
| SCHEMBL15220429 | 0.84 | KDM1A (0.41) | PGRKDM1ANR3C1ARTRPA1 | |
| SCHEMBL13185233 | 0.83 | AR (0.47) | PGRNR3C1AR | |
| SCHEMBL22763313 | 0.83 | DPP4 (0.49) | DPP4MAPK1 | |
| SCHEMBL498818 | 0.83 | DPP4 (0.49) | DPP4MAPK1 | |
| 2,5-Thiophenedinitrile SCHEMBL996528 | 0.82 | — | — | |
| SCHEMBL26503081 | 0.82 | PGR (0.37) | PGRKDM1ANR3C1ARTRPA1 | |
| SCHEMBL9777540 | 0.80 | PGR (0.33) | PGRKDM1ANR3C1AR | |
| SCHEMBL4007009 | 0.80 | PGR (0.40) | PGRKDM1ANR3C1ARTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| EP-1357912-B1 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-04-25 | — | — | EP | disclosed |
| US-20120041356-A1 | PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE | QLT INC. (CA) | 2012-02-16 | — | — | US | disclosed |
| US-8106038-B2 | Method for reducing or preventing PDT related inflammation | QLT INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| EP-2379109-A1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | Qlt Inc. (CA) | 2011-10-26 | — | — | EP | disclosed |
| US-8034803-B2 | Treating an occult choroidal neovascular lesion | QLT INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| US-7850981-B2 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT, INC. (CA) | 2010-12-14 | — | — | US | disclosed |
| EP-1229937-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT Inc. (CA) | 2002-08-14 | — | — | EP | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001085213-A2 | SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001035996-A2 | USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001035997-A2 | USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS | QLT INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
| US-5753692-A | PLANT EXTRACTS, IMMUNOSTIMULANTS TREATING IMMUNODEFICIENCY DISEASES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1998-05-19 | — | — | US | disclosed |
| US-5747525-A | ANTITUMOR AGENTS OF OLIGOMERS OF THIOPHENE | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1998-05-05 | — | — | US | disclosed |
| US-5602170-A | ADMINISTERING ANTIIFLAMMATORY AGENT | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1997-02-11 | — | — | US | disclosed |
| US-5045563-A | Terthienyl Compound | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY MINISTER OF NATIONAL DEFENCE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | PGR 1766/4885KDM1A 3650/4885NR3C1 4547/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | PGR 1675/4885KDM1A 4394/4885NR3C1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.